PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y [Yahoo! Finance]
Pacific Biosciences of California, Inc. (PACB)
Last pacific biosciences of california, inc. earnings: 2/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacificbiosciences.com
Company Research
Source: Yahoo! Finance
The adjusted loss per share beat the Zacks Consensus Estimate by 15%. The company's GAAP loss per share was 22 cents in the quarter, narrower than the year-ago period's loss of 26 cents. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. PacBio registered revenues of $40 million, down 28.2% year over year. The figure missed the Zacks Consensus Estimate by 4.6%. PacBio's revenues from the Americas totaled $20.1 million, down 31% year over year. This was primarily due to a decline in Revio shipments. In the Asia-Pacific region, PacBio recorded revenues of 10.8 million, reflecting a decline of 32% year over year. Europe, the Middle East and Africa (EMEA) region registered revenues of $9.1 million, which decreased 17% year over year. Product revenues amounted to $35.3 million, up 11.2% from the year-ago level. PacBio shipped 22 Revio sequencing systems in the third quarter, which brought the company's installed base to 247 Revio systems as of Sept. 3
Show less
Read more
Impact Snapshot
Event Time:
PACB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PACB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PACB alerts
High impacting Pacific Biosciences of California, Inc. news events
Weekly update
A roundup of the hottest topics
PACB
News
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Scotiabank from $7.00 to $6.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.MarketBeat
- Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target raised by analysts at Piper Sandler from $2.00 to $2.50. They now have a "neutral" rating on the stock.MarketBeat
- Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts [Yahoo! Finance]Yahoo! Finance
- PacBio to Present at Upcoming Investor ConferencesGlobeNewswire
PACB
Earnings
- 11/7/24 - Beat
PACB
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form 8-K
- 11/12/24 - Form 10-Q
- PACB's page on the SEC website